Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection

被引:134
|
作者
Theil, FP [1 ]
Guentert, TW [1 ]
Haddad, S [1 ]
Poulin, P [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Nonclin Drug Safety, Pharma Res, CH-4070 Basel, Switzerland
关键词
drug discovery; drug development; partition coefficients; PBPK modeling; pharmacokinetics; toxicokinetics; QSAR;
D O I
10.1016/S0378-4274(02)00374-0
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The present paper proposes a modeling and simulation strategy for the prediction of pharmacokinetics (PK) of drug candidates by using currently available in silico and in vitro based prediction tools for absorption, distribution, metabolism and excretion (ADME). These methods can be used to estimate specific ADME parameters (such as rate and extent of absorption into portal vein, volume of distribution, metabolic clearance in the liver). They can also be part of a physiologically based pharmacokinetic (PBPK) model to simulate concentration-time profiles in tissues and plasma resulting from the overall PK after intravenous or oral administration. Since the ADME prediction tools are built only on commonly generated in silico and in vitro data, they can be applied already in early drug discovery, prior to any in vivo study. With the suggested methodology, the following advantages of the mechanistic PBPK modeling framework can now be utilized to explore potential clinical candidates already in drug discovery: (i) prediction of plasma (blood) and tissue PK of drug candidates prior to in vivo experiments, (ii) supporting a better mechanistic understanding of PK properties, as well as helping the development of more rationale PK-PD relationships from tissue kinetic data predicted, and hence facilitating a more rational decision during clinical candidate selection, and (iii) the extrapolation across species, routes of administration and dose levels. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 49
页数:21
相关论文
共 50 条
  • [41] Drug metabolism in drug discovery and development
    Zhang, Zhoupeng
    Tang, Wei
    ACTA PHARMACEUTICA SINICA B, 2018, 8 (05) : 721 - 732
  • [42] Drug metabolism in drug discovery and development
    Zhoupeng Zhang
    Wei Tang
    Acta Pharmaceutica Sinica B, 2018, 8 (05) : 721 - 732
  • [43] Rodent Models of Persistent Pain in Drug Discovery and Development
    Eckert, William A., III
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (10) : 1590 - 1595
  • [44] On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson's Psychosis
    Hacksell, Uli
    Burstein, Ethan S.
    McFarland, Krista
    Mills, Roger G.
    Williams, Hilde
    NEUROCHEMICAL RESEARCH, 2014, 39 (10) : 2008 - 2017
  • [46] A Review on Recent Rational Approaches to Drug Design, Development and Its Discovery
    Bisht, Dheeraj
    Arya, Rajeshwar Kamal Kant
    Pal, Govind Raj
    Singh, Ravindra Pratap
    INTERNATIONAL JOURNAL OF LIFE SCIENCE AND PHARMA RESEARCH, 2020, 10 (04): : P96 - P108
  • [47] The Pharmacokinetic/Pharmacodynamic Research Tool (Presto): An Advanced Concept for Rational Drug Development
    Gernot Göller
    Wolfgang Mück
    Dieter Koss
    Peter Nörtersheuser
    Michael Osswald
    Andreas Kovar
    Christian Zurth
    Hans Poland
    Drug information journal : DIJ / Drug Information Association, 2002, 36 (1): : 57 - 66
  • [48] Structural identifiability of physiologically based pharmacokinetic models
    Yates, JWT
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (04) : 421 - 439
  • [49] Physiologically Based Pharmacokinetic (PBPK) Models for Ethanol
    Plawecki, Martin H.
    Han, Jae-Joon
    Doerschuk, Peter C.
    Ramchandani, Vijay A.
    O'Connor, Sean J.
    IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 2008, 55 (12) : 2691 - 2700
  • [50] The pharmacokinetic/pharmacodynamic research tool (PRESTO):: An advanced concept for rational drug development
    Göller, G
    Mück, W
    Koss, D
    Nörtersheuser, P
    Osswald, M
    Kovar, A
    Zurth, C
    Poland, H
    DRUG INFORMATION JOURNAL, 2002, 36 (01): : 57 - 66